Mercedes BelÃ©n GonzÃ¡lez

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2781656/publications.pdf

Version: 2024-02-01

204 papers	7,134 citations	50276 46 h-index	85541 71 g-index

215 all docs	215 docs citations	215 times ranked	6403 citing authors

#	Article	IF	Citations
1	Development and Evaluation of 2-Amino-7-Fluorophenazine 5,10-Dioxide Polymeric Micelles as Antitumoral Agents for 4T1 Breast Cancer. Polymers, 2022, 14, 71.	4.5	2
2	Identification and characterization of human interferon alpha inhibitors through a WISH cell line-based reporter gene assay. Bioorganic Chemistry, 2020, 94, 103372.	4.1	2
3	New aryloxyâ€quinone derivatives with promising activity on Trypanosoma cruzi. Archiv Der Pharmazie, 2020, 353, e1900213.	4.1	12
4	In vitro and in silico evaluations of new aryloxy-1,4-naphthoquinones as anti-Trypanosoma cruzi agents. Medicinal Chemistry Research, 2020, 29, 665-674.	2.4	11
5	Selective Hypoxiaâ€Cytotoxin 7â€Fluoroâ€2â€Aminophenazine 5,10â€Dioxide: Toward â€œCandidateâ€toâ€Drugâ€•Stage in the Drugâ€Development Pipeline. ChemistrySelect, 2019, 4, 9396-9402.	1.5	5
6	Identification of N-Oxide-Containing Aromatic Heterocycles as Pharmacophores for Rumen Fermentation Modifiers. Metabolites, 2019, 9, 62.	2.9	1
7	Formation of dendrimer-guest complexes as a strategy to increase the solubility of a phenazine N, Nâ€²-dioxide derivative with antitumor activity. Heliyon, 2019, 5, e01528.	3.2	12
8	Chemosensitizer effect of cisplatin-treated bladder cancer cells by phenazine-5,10-dioxides. Environmental Toxicology and Pharmacology, 2019, 69, 9-15.	4.0	8
9	Novel coumarins active against Trypanosoma cruzi and toxicity assessment using the animal model Caenorhabditis elegans. BMC Pharmacology & Toxicology, 2019, 20, 76.	2.4	7
10	Polypharmacology in the Treatment of Chagas Disease. Current Medicinal Chemistry, 2019, 26, 4476-4489.	2.4	10
11	Inhibition of LDL oxidation and inflammasome assembly by nitroaliphatic derivatives. Potential use as anti-inflammatory and anti-atherogenic agents. European Journal of Medicinal Chemistry, 2018, 159, 178-186.	5.5	3
12	Slowed Development of Natural Products for Chagas Disease, how to Move Forward?. , 2018, , .		2
13	Novel and Selective Rhipicephalus microplus Triosephosphate Isomerase Inhibitors with Acaricidal Activity. Veterinary Sciences, 2018, 5, 74.	1.7	13
14	Looking for combination of benznidazole and Trypanosoma cruzi-triosephosphate isomerase inhibitors for Chagas disease treatment. Memorias Do Instituto Oswaldo Cruz, 2018, 113, 153-160.	1.6	12
15	Synthesis and in vivo proof of concept of a BODIPY-based fluorescent probe as a tracer for biodistribution studies of a new anti-Chagas agent. RSC Advances, 2017, 7, 7983-7989.	3.6	9
16	Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and inÂvivo biological properties. European Journal of Medicinal Chemistry, 2017, 136, 223-234.	5.5	9
17	Development, validation and application of a GCâ€“MS method for the simultaneous detection and quantification of neutral lipid species in Trypanosoma cruzi. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1061-1062, 225-232.	2.3	9
18	3-(Benzyloxy)-1-(5-[¹⁸F]fluoropentyl)-5-nitro-1H-indazole: a PET radiotracer to measure acetylcholinesterase in brain. Future Medicinal Chemistry, 2017, 9, 983-994.	2.3	4

#	Article	IF	Citations
19	Multi-Anti-Parasitic Activity of Arylidene Ketones and Thiazolidene Hydrazines against Trypanosoma cruzi and Leishmania spp.. Molecules, 2017, 22, 709.	3.8	25
20	Potent and Selective Inhibitors of Trypanosoma cruzi Triosephosphate Isomerase with Concomitant Inhibition of Cruzipain: Inhibition of Parasite Growth through Multitarget Activity. ChemMedChem, 2016, 11, 1328-1338.	3.2	38
21	New hybrid bromopyridine-chalcones as in vivo phase II enzyme inducers: potential chemopreventive agents. MedChemComm, 2016, 7, 2395-2409.	3.4	8
22	Synthesis and biological evaluation of quinoxaline di- N -oxide derivatives with in vitro trypanocidal activity. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 903-906.	2.2	16
23	In vivo phase II-enzymes inducers, as potential chemopreventive agents, based on the chalcone and furoxan skeletons. Bioorganic and Medicinal Chemistry, 2016, 24, 1665-1674.	3.0	18
24	Identification of Chalcones as Fasciola hepatica Cathepsin L Inhibitors Using a Comprehensive Experimental and Computational Approach. PLoS Neglected Tropical Diseases, 2016, 10, e0004834.	3.0	23
25	Analgesic and Anti-Inflammatory Properties of Arylnitroalkenes. Inflammation and Allergy: Drug Targets, 2015, 14, 19-28.	1.8	1
26	3-H-[1,2]Dithiole as a New Anti-Trypanosoma cruzi Chemotype: Biological and Mechanism of Action Studies. Molecules, 2015, 20, 14595-14610.	3.8	11
27	Preparation and Biological Evaluation of ^{99m}Tc-Labelled Phenazine Dioxides as Potential Tracers for Hypoxia Imaging. Current Radiopharmaceuticals, 2015, 8, 56-61.	0.8	2
28	Expanding the family of heteroleptic oxidovanadium(IV) compounds with salicylaldehyde semicarbazones and polypyridyl ligands showing anti-Trypanosoma cruzi activity. Journal of Inorganic Biochemistry, 2015, 147, 116-125.	3.5	31
29	Molecular docking and molecular dynamics simulation studies of Trypanosoma cruzi triosephosphate isomerase inhibitors. Insights into the inhibition mechanism and selectivity. Journal of Molecular Graphics and Modelling, 2015, 58, 40-49.	2.4	30
30	Design, synthesis and inÂvitro trypanocidal and leishmanicidal activities of novel semicarbazone derivatives. European Journal of Medicinal Chemistry, 2015, 100, 24-33.	5.5	18
31	A new ruthenium cyclopentadienyl azole compound with activity on tumor cell lines and trypanosomatid parasites. Journal of Coordination Chemistry, 2015, 68, 2923-2937.	2.2	37
32	New aryloxy-quinone derivatives as potential anti-Chagasic agents: synthesis, trypanosomicidal activity, electrochemical properties, pharmacophore elucidation and 3D-QSAR analysis. RSC Advances, 2015, 5, 65153-65166.	3.6	24
33	Development of bis-thiazoles as inhibitors of triosephosphate isomerase from Trypanosoma cruzi. Identification of new non-mutagenic agents that are active inÂvivo. European Journal of Medicinal Chemistry, 2015, 100, 246-256.	5.5	37
34	Searching phase II enzymes inducers, from Michael acceptor-[1,2]dithiolethione hybrids, as cancer chemopreventive agents. Future Medicinal Chemistry, 2015, 7, 857-871.	2.3	12
35	New hits as phase II enzymes inducers from a focused library with heteroatomâ€“heteroatom and Michael-acceptor motives. Future Science OA, 2015, 1, FSO20.	1.9	4
36	Identification of a New Amide-Containing Thiazole as a Drug Candidate for Treatment of Chagas' Disease. Antimicrobial Agents and Chemotherapy, 2015, 59, 1398-1404.	3.2	39

#	Article	IF	Citations
37	In Vivo Anti-Trypanosoma cruzi Activity of Hydro-Ethanolic Extract and Isolated Active Principles from Aristeguietia glutinosa and Mechanism of Action Studies. Molecules, 2014, 19, 8488-8502.	3.8	20
38	Initial studies on mechanism of action and cell death of activeN-oxide-containing heterocycles inTrypanosoma cruziepimastigotesin vitro. Parasitology, 2014, 141, 682-696.	1.5	9
39	New chemotypes as Trypanosoma cruzi triosephosphate isomerase inhibitors: a deeper insight into the mechanism of inhibition. Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, 29, 198-204.	5.2	19
40	A serendipitous one-step conversion of 3H-1,2-dithiole-3-thione to (E)-3-[1-(alkylthio)alkylidene]-3H-1,2-dithiole: an experimental and theoretical study. Molecular Diversity, 2014, 18, 285-294.	3.9	7
41	Trypanosoma cruzi chemical proteomics using immobilized benznidazole. Experimental Parasitology, 2014, 140, 33-38.	1.2	14
42	Arylnitroalkenes as scavengers of macrophage-generated oxidants. European Journal of Medicinal Chemistry, 2014, 74, 31-40.	5.5	8
43	Optimization of Antitrypanosomatid Agents: Identification of Nonmutagenic Drug Candidates with in Vivo Activity. Journal of Medicinal Chemistry, 2014, 57, 3984-3999.	6.4	40
44	Synthesis and biological characterization of new aryloxyindole-4,9-diones as potent trypanosomicidal agents. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3919-3922.	2.2	13
45	Evaluation of different PAMAM dendrimers as molecular vehicle of 1,2,4-triazine N-oxide derivative with potential antitumor activity. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2014, 79, 65-73.	1.6	8
46	Mutagenicity of N-oxide Containing Heterocycles and Related Compounds: Experimental and Theoretical Studies. Current Topics in Medicinal Chemistry, 2014, 14, 1374-1387.	2.1	18
47	Novel quinoxaline 1,4-di-N-oxide derivatives as new potential antichagasic agents. European Journal of Medicinal Chemistry, 2013, 66, 324-334.	5.5	44
48	Biotransformation of Phenazine 5,10-Dioxides under Hypoxic Conditions as an Example of Activation of Anticancer Prodrug: An Interdisciplinary Experiment for Biochemistry or Organic Chemistry. Journal of Chemical Education, 2013, 90, 1388-1391.	2.3	4
49	1,2,4-thiadiazol-5(4H)-ones: a new class of selective inhibitors of Trypanosoma cruzi triosephosphate isomerase. Study of the mechanism of inhibition. Journal of Enzyme Inhibition and Medicinal Chemistry, 2013, 28, 981-989.	5.2	13
50	Evaluating 5-Nitrofurans as Trypanocidal Agents. Antimicrobial Agents and Chemotherapy, 2013, 57, 1638-1647.	3.2	32
51	Phenazine N,Nâ€²-dioxide scaffold as selective hypoxic cytotoxin pharmacophore. Structural modifications looking for further DNA topoisomerase II-inhibition activity. MedChemComm, 2013, 4, 595.	3.4	14
52	Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates. European Journal of Medicinal Chemistry, 2013, 59, 64-74.	5.5	57
53	New oxidovanadium(IV) N -acylhydrazone complexes: Promising antileishmanial and antitrypanosomal agents. European Journal of Medicinal Chemistry, 2013, 62, 20-27.	5.5	57
54	Oxidovanadium(IV) and dioxidovanadium(V) complexes of tridentate salicylaldehyde semicarbazones: Searching for prospective antitrypanosomal agents. Journal of Inorganic Biochemistry, 2013, 127, 150-160.	3.5	59

#	Article	IF	Citations
55	A new series of heteroleptic oxidovanadium(iv) compounds with phenanthroline-derived co-ligands: selective Trypanosoma cruzi growth inhibitors. Dalton Transactions, 2013, 42, 11900.	3.3	56
56	Identification of novel benzimidazole derivatives as anti-Trypanosoma cruzi agents: solid-phase synthesis, structureâ€“activity relationships and molecular docking studies. Future Medicinal Chemistry, 2013, 5, 1719-1732.	2.3	8
57	Artificial Neural Networks Based on CODES Descriptors in Pharmacology: Identification of Novel Trypanocidal Drugs against Chagas Disease. Current Computer-Aided Drug Design, 2013, 9, 130-140.	1.2	1
58	Study ofTrypanosoma cruziepimastigote cell death by NMR-visible mobile lipid analysis. Parasitology, 2012, 139, 506-515.	1.5	9
59	Coordination of 3-aminoquinoxaline-2-carbonitrile 1,4-dioxides to antimony(III) as a strategy for anti-Trypanosoma cruzi activity improvement. Medicinal Chemistry Research, 2012, 21, 4120-4128.	2.4	5
60	Amidines bearing benzofuroxan or benzimidazole 1,3-dioxide core scaffolds as Trypanosoma cruzi-inhibitors: structural basis for their interactions with cruzipain. MedChemComm, 2012, 3, 90-101.	3.4	12
61	Quinoxaline derivatives: a patent review (2006 â€“ present). Expert Opinion on Therapeutic Patents, 2012, 22, 1289-1302.	5.0	48
62	Bisphosphonate metal complexes as selective inhibitors of Trypanosoma cruzi farnesyl diphosphate synthase. Dalton Transactions, 2012, 41, 6468.	3.3	32
63	Activity on Trypanosoma cruzi, erythrocytes lysis and biologically relevant physicochemical properties of Pd(II) and Pt(II) complexes of thiosemicarbazones derived from 1-indanones. Journal of Inorganic Biochemistry, 2012, 117, 270-276.	3.5	16
64	Design, Synthesis, and Pharmacological Evaluation of Novel Hybrid Compounds to Treat Sickle Cell Disease Symptoms. Part II: Furoxan Derivatives. Journal of Medicinal Chemistry, 2012, 55, 7583-7592.	6.4	49
65	Identification of Thioredoxin Glutathione Reductase Inhibitors That Kill Cestode and Trematode Parasites. PLoS ONE, 2012, 7, e35033.	2.5	34
66	Bioactive-guided Identification of Labdane Diterpenoids from Aerial Parts of Aristeguietia glutinosa as anti-Trypanosoma cruzi agents. Natural Product Communications, 2012, 7, 1934578X1200700.	0.5	2
67	Effect of complexation of 3-aminoquinoxaline-2-carbonitrile 1,4-dioxides with palladium and copper on their anti-T. cruzi activity. Medicinal Chemistry Research, 2012, 21, 1439-1444.	2.4	8
68	Discovery of new orally effective analgesic and anti-inflammatory hybrid furoxanyl N-acylhydrazone derivatives. Bioorganic and Medicinal Chemistry, 2012, 20, 2158-2171.	3.0	62
69	Reaction of isatin with alkylating agents with acidic methylenes. Tetrahedron Letters, 2012, 53, 2514-2517.	1.4	25
70	2-Acetylpyridine- and 2-benzoylpyridine-derived thiosemicarbazones and their antimony(III) complexes exhibit high anti-trypanosomal activity. Polyhedron, 2012, 31, 614-621.	2.2	36
71	Bioactive-guided identification of labdane diterpenoids from aerial parts of Aristeguietia glutinosa as anti-Trypanosoma cruzi agents. Natural Product Communications, 2012, 7, 1139-42.	0.5	7
72	3-Trifluoromethylquinoxaline N,Nâ€²-Dioxides as Anti-Trypanosomatid Agents. Identification of Optimal Anti-T. cruzi Agents and Mechanism of Action Studies. Journal of Medicinal Chemistry, 2011, 54, 3624-3636.	6.4	49

#	Article	IF	Citations
73	Novel compounds to combat trypanosomatid infections: a medicinal chemical perspective. Expert Opinion on Therapeutic Patents, 2011, 21, 699-715.	5.0	13
74	Antiparasitic prodrug nifurtimox: revisiting its activation mechanism. Future Microbiology, 2011, 6, 847-850.	2.0	12
75	2Dâ€•and 3Dâ€Quantitative Structureâ€Activity Relationship Studies for a Series of Phenazine N,Nâ€™â€Dioxide as Antitumour Agents. Chemical Biology and Drug Design, 2011, 78, 960-968.	3.2	7
76	6-Methylnitroarachidonate: A novel esterified nitroalkene that potently inhibits platelet aggregation and exerts cGMP-mediated vascular relaxation. Free Radical Biology and Medicine, 2011, 50, 411-418.	2.9	23
77	Thiosemicarbazones derived from 1-indanones as new anti-Trypanosoma cruzi agents. Bioorganic and Medicinal Chemistry, 2011, 19, 6818-6826.	3.0	50
78	Potent 5-nitrofuran derivatives inhibitors of Trypanosoma cruzi growth: Electrochemical, spectroscopic and biological studies. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2011, 79, 312-319.	3.9	16
79	Genetic toxicology and preliminaryin vivostudies of nitric oxide donor tocopherol analogs as potential new class of antiatherogenic agents. Drug and Chemical Toxicology, 2011, 34, 285-293.	2.3	10
80	Novel Phenazine 5,10-Dioxides Release ^{â€¢}OH in Simulated Hypoxia and Induce Reduction of Tumour Volume In Vivo. ISRN Pharmacology, 2011, 2011, 1-11.	1.6	12
81	Coordination of nitro-thiosemicarbazones to ruthenium(II) as a strategy for anti-trypanosomal activity improvement. European Journal of Medicinal Chemistry, 2010, 45, 2847-2853.	5.5	33
82	Structural relationships in the solid state of the anti-chagas agent (E)-phenylethenylbenzofuroxan. Molecular Diversity, 2010, 14, 643-652.	3.9	4
83	Mode of action of Nifurtimox and N-oxide-containing heterocycles against Trypanosoma cruzi: Is oxidative stress involved?. Biochemical Pharmacology, 2010, 79, 1736-1745.	4.4	94
84	Risedronate metal complexes potentially active against Chagas disease. Journal of Inorganic Biochemistry, 2010, 104, 1252-1258.	3.5	58
85	New heteroaryl nitrones with spin trap properties: Identification of a 4-furoxanyl derivative with excellent properties to be used in biological systems. Bioorganic and Medicinal Chemistry, 2010, 18, 795-802.	3.0	25
86	Study of benzo[a]phenazine 7,12-dioxide as selective hypoxic cytotoxin-scaffold. Identification of aerobic-antitumoral activity through DNA fragmentation. Bioorganic and Medicinal Chemistry, 2010, 18, 4433-4440.	3.0	24
87	Identification of chalcones as in vivo liver monofunctional phase II enzymes inducers. Bioorganic and Medicinal Chemistry, 2010, 18, 5391-5399.	3.0	27
88	Anti-T. cruzi activities and QSAR studies of 3-arylquinoxaline-2-carbonitrile di-N-oxides. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4831-4835.	2.2	22
89	Synthesis and in vitro activity of limonene derivatives against Leishmania and Trypanosoma. European Journal of Medicinal Chemistry, 2010, 45, 1524-1528.	5.5	40
90	Naftifine-analogues as anti-Trypanosoma cruzi agents. European Journal of Medicinal Chemistry, 2010, 45, 2154-2164.	5.5	33

#	Article	IF	Citations
91	Structural modifications on the phenazine N,Nâ€²-dioxide-scaffold looking for new selective hypoxic cytotoxins. European Journal of Medicinal Chemistry, 2010, 45, 5362-5369.	5.5	24
92	Massive screening yields novel and selective Trypanosoma cruzi triosephosphate isomerase dimer-interface-irreversible inhibitors with anti-trypanosomal activity. European Journal of Medicinal Chemistry, 2010, 45, 5767-5772.	5.5	47
93	Synthetic Medicinal Chemistry in Chagasâ€™ Disease: Compounds at The Final Stage of â€œHit-To-Leadâ€•Phase. Pharmaceuticals, 2010, 3, 810-838.	3.8	49
94	Development of second generation amidinohydrazones, thio- and semicarbazones as Trypanosoma cruzi-inhibitors bearing benzofuroxan and benzimidazole 1,3-dioxide core scaffolds. MedChemComm, 2010, 1, 216.	3.4	34
95	Targets for Anti-T. cruzi Drugs in the Post-Genomic Era. Current Enzyme Inhibition, 2010, 6, 195-210.	0.4	7
96	Heterocyclic-2-carboxylic Acid (3-Cyano-1,4-di-N-oxidequinoxalin-2-yl)amide Derivatives as Hits for the Development of Neglected Disease Drugs. Molecules, 2009, 14, 2256-2272.	3.8	41
97	5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene. Bioorganic and Medicinal Chemistry, 2009, 17, 7500-7509.	3.0	46
98	In vitro and in vivo antitrypanosomatid activity of 5-nitroindazoles. European Journal of Medicinal Chemistry, 2009, 44, 1034-1040.	5.5	41
99	5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: Preliminary in vivo studies. European Journal of Medicinal Chemistry, 2009, 44, 3909-3914.	5.5	10
100	Platinum-based complexes of bioactive 3-(5-nitrofuryl)acroleine thiosemicarbazones showing anti-Trypanosoma cruzi activity. Journal of Inorganic Biochemistry, 2009, 103, 411-418.	3.5	75
101	Study of 5-nitroindazoles' anti-Trypanosoma cruzi mode of action: Electrochemical behaviour and ESR spectroscopic studies. European Journal of Medicinal Chemistry, 2009, 44, 1545-1553.	5.5	44
102	Second generation of 2H-benzimidazole 1,3-dioxide derivatives as anti-trypanosomatid agents: Synthesis, biological evaluation, and mode of action studies. European Journal of Medicinal Chemistry, 2009, 44, 4426-4433.	5.5	35
103	Effect of ruthenium complexation on trypanocidal activity of 5-nitrofuryl containing thiosemicarbazones. European Journal of Medicinal Chemistry, 2009, 44, 4937-4943.	5.5	41
104	Anti-trypanosomatid benzofuroxans and deoxygenated analogues: Synthesis using polymer-supported triphenylphosphine, biological evaluation and mechanism of action studies. European Journal of Medicinal Chemistry, 2009, 44, 5055-5065.	5.5	33
105	Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates. Bioorganic and Medicinal Chemistry, 2009, 17, 641-652.	3.0	94
106	Cytotoxic palladium complexes of bioreductive quinoxaline N1,N4-dioxide prodrugs. Bioorganic and Medicinal Chemistry, 2009, 17, 1623-1629.	3.0	25
107	New potent imidazoisoquinolinone derivatives as anti-Trypanosoma cruzi agents: Biological evaluation and structureâ€“activity relationships. Bioorganic and Medicinal Chemistry, 2009, 17, 1437-1444.	3.0	41
108	New potent 5-nitroindazole derivatives as inhibitors of Trypanosoma cruzi growth: Synthesis, biological evaluation, and mechanism of action studies. Bioorganic and Medicinal Chemistry, 2009, 17, 8186-8196.	3.0	41

#	Article	IF	Citations
109	Interaction studies between human Î±-tocopherol transfer protein and nitric oxide donor tocopherol analogues with LDL-protective activity. Bioorganic and Medicinal Chemistry, 2009, 17, 8143-8148.	3.0	3
110	Cytotoxic, mutagenic and genotoxic effects of new anti-T. cruzi 5-phenylethenylbenzofuroxans. Contribution of phase I metabolites on the mutagenicity induction. Toxicology Letters, 2009, 190, 140-149.	0.8	31
111	New copper-based complexes with quinoxaline N1,N4-dioxide derivatives, potential antitumoral agents. Journal of Inorganic Biochemistry, 2008, 102, 119-126.	3.5	58
112	Potent in vitro anti-Trypanosoma cruzi activity of pyridine-2-thiol N-oxide metal complexes having an inhibitory effect on parasite-specific fumarate reductase. Journal of Biological Inorganic Chemistry, 2008, 13, 723-735.	2.6	56
113	Evaluation of a new dendrimeric structure as prospective drugs carrier for intravenous administration of antichagasic active compounds. Journal of Physical Organic Chemistry, 2008, 21, 1079-1085.	1.9	21
114	Comparative spectroscopic and electrochemical study of nitroindazoles: 3-Alcoxy, 3-hydroxy and 3-oxo derivatives. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2008, 70, 557-563.	3.9	17
115	Development of a HPLC method for the determination of antichagasic phenylethenylbenzofuroxans and its major synthetic secondary products in the chemical production processes. Journal of Pharmaceutical and Biomedical Analysis, 2008, 47, 88-94.	2.8	8
116	Platinum(II) metal complexes as potential anti-Trypanosoma cruzi agents. Journal of Inorganic Biochemistry, 2008, 102, 1033-1043.	3.5	74
117	Preparation and characterization of technetium and rhenium tricarbonyl complexes bearing the 4-nitrobenzyl moiety as potential bioreductive diagnostic radiopharmaceuticals. In vitro and in vivo studies. European Journal of Medicinal Chemistry, 2008, 43, 741-748.	5.5	26
118	4-Nitroacetophenone-derived thiosemicarbazones and their copper(II) complexes with significant in vitro anti-trypanosomal activity. European Journal of Medicinal Chemistry, 2008, 43, 939-948.	5.5	59
119	Pyrimido[1,2-a]quinoxaline 6-oxide and phenazine 5,10-dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi. European Journal of Medicinal Chemistry, 2008, 43, 1737-1741.	5.5	28
120	In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas' disease. European Journal of Medicinal Chemistry, 2008, 43, 2229-2237.	5.5	18
121	Heteroallyl-containing 5-nitrofuranes as new anti-Trypanosoma cruzi agents with a dual mechanism of action. Bioorganic and Medicinal Chemistry, 2008, 16, 569-577.	3.0	45
122	Imidazolidines as new anti-Trypanosoma cruzi agents: Biological evaluation and structureâ€“activity relationships. Bioorganic and Medicinal Chemistry, 2008, 16, 2226-2234.	3.0	66
123	New trypanocidal hybrid compounds from the association of hydrazone moieties and benzofuroxan heterocycle. Bioorganic and Medicinal Chemistry, 2008, 16, 6995-7004.	3.0	47
124	Furoxan-, alkylnitrate-derivatives and related compounds as anti-trypanosomatid agents: Mechanism of action studies. Bioorganic and Medicinal Chemistry, 2008, 16, 7900-7907.	3.0	42
125	Arylethenylbenzofuroxan Derivatives as Drugs for Chagas Disease: Multigram Batch Synthesis using a Wittigâ^'Boden Process. Organic Process Research and Development, 2008, 12, 156-162.	2.7	20
126	Convenient Route to Primary (Z)-Allyl Amines and Homologs. Synthetic Communications, 2008, 39, 29-47.	2.1	9

#	Article	IF	Citations
127	Modeling anti-Trypanosoma cruzi Activity of N-Oxide Containing Heterocycles. Journal of Chemical Information and Modeling, 2008, 48, 213-219.	5.4	19
128	Antitumoral Effect of Phenazine N⁵,N¹⁰-Dioxide Derivatives on Caco-2 Cells. Chemical Research in Toxicology, 2008, 21, 1578-1585.	3.3	25
129	Heteroarylnitrones as Drugs for Neurodegenerative Diseases: Synthesis, Neuroprotective Properties, and Free Radical Scavenger Properties. Journal of Medicinal Chemistry, 2008, 51, 6150-6159.	6.4	48
130	Differential Enzymatic Reductions Governing the Differential Hypoxia-Selective Cytotoxicities of Phenazine 5,10-Dioxides. Chemical Research in Toxicology, 2008, 21, 1900-1906.	3.3	28
131	Anti-T. cruzi Agents: Our Experience in the Evaluation of More than Five Hundred Compounds. Mini-Reviews in Medicinal Chemistry, 2008, 8, 1355-1383.	2.4	40
132	Quinoxaline 1,4-Dioxide and Phenazine 5,10-Dioxide. Chemistry and Biology. , 2007, , 179-211.		24
133	In VivoAnti-Chagas Vinylthio-, Vinylsulfinyl-, and Vinylsulfonylbenzofuroxan Derivativesâ€¡. Journal of Medicinal Chemistry, 2007, 50, 6004-6015.	6.4	35
134	Benzofuroxan and Furoxan. Chemistry and Biology. Topics in Heterocyclic Chemistry, 2007, , 265-308.	0.2	45
135	Interaction energies of nitrofurans with trypanothione reductase and glutathione reductase studied by molecular docking. Computational and Theoretical Chemistry, 2007, 818, 7-22.	1.5	10
136	Second generation of 5-ethenylbenzofuroxan derivatives as inhibitors of Trypanosoma cruzi growth: Synthesis, biological evaluation, and structureâ€“activity relationships. Bioorganic and Medicinal Chemistry, 2007, 15, 2768-2781.	3.0	43
137	Synthetic chalcones, flavanones, and flavones as antitumoral agents: Biological evaluation and structureâ€“activity relationships. Bioorganic and Medicinal Chemistry, 2007, 15, 3356-3367.	3.0	260
138	Second generation of Î±-tocopherol analogs-nitric oxide donors: Synthesis, physicochemical, and biological characterization. Bioorganic and Medicinal Chemistry, 2007, 15, 6262-6272.	3.0	24
139	Structure of indazole N1-oxide derivatives studied by X-ray, theoretical methods, 1H, 13C, 15N NMR and EI/MS. Journal of Molecular Structure, 2007, 871, 98-107.	3.6	8
140	2-Benzyl-2-methyl-2H-benzimidazole 1,3-dioxide derivatives: Spectroscopic and theoretical study. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2007, 67, 540-549.	3.9	7
141	Vibrational spectra of palladium 5-nitrofuryl thiosemicarbazone complexes: Experimental and theoretical study. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2007, 68, 341-348.	3.9	49
142	2H-Benzimidazole 1,3-Dioxide Derivatives:Â A New Family of Water-Soluble Anti-Trypanosomatid Agentsâ€. Journal of Medicinal Chemistry, 2006, 49, 3215-3224.	6.4	68
143	Novel Antitrypanosomal Agents Based on Palladium Nitrofurylthiosemicarbazone Complexes:Â DNA and Redox Metabolism as Potential Therapeutic Targetsâ€. Journal of Medicinal Chemistry, 2006, 49, 3322-3331.	6.4	157
144	Solubilization and Release Properties of Dendrimers. Evaluation as Prospective Drug Delivery Systems. Supramolecular Chemistry, 2006, 18, 633-643.	1.2	33

#	Article	IF	Citations
145	New potent 5-nitrofuryl derivatives asÂinhibitors ofÂTrypanosomaÂcruzi growth. 3D-QSAR (CoMFA) studies. European Journal of Medicinal Chemistry, 2006, 41, 457-466.	5.5	23
146	Design andÂevaluation ofÂâ€œ3 + 1â€•mixed ligand oxorhenium andÂoxotechnetium complexes bearing aÂnitroaromatic group with potential application inÂnuclear medicine oncology. European Journal of Medicinal Chemistry, 2006, 41, 1144-1152.	5.5	27
147	Nitrofurylsemicarbazone Rhenium andÂRuthenium Complexes asÂAnti-trypanosomal Agents. European Journal of Medicinal Chemistry, 2006, 41, 1231-1239.	5.5	35
148	Indazole N-oxide derivatives as antiprotozoal agents: Synthesis, biological evaluation and mechanism of action studies. Bioorganic and Medicinal Chemistry, 2006, 14, 3467-3480.	3.0	78
149	Improving anti-trypanosomal activity of 3-aminoquinoxaline-2-carbonitrile N1,N4-dioxide derivatives by complexation with vanadium. Bioorganic and Medicinal Chemistry, 2006, 14, 5503-5509.	3.0	76
150	ESR and electrochemical study of 5-nitroindazole derivatives with antiprotozoal activity. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2006, 63, 36-42.	3.9	18
151	Novel vanadyl complexes with quinoxaline N1,N4-dioxide derivatives as potent in vitro insulin-mimetic compounds. Journal of Inorganic Biochemistry, 2006, 100, 281-287.	3.5	29
152	Selective hypoxia-cytotoxins based on vanadyl complexes with 3-aminoquinoxaline-2-carbonitrile-N1,N4-dioxide derivatives. Journal of Inorganic Biochemistry, 2006, 100, 1358-1367.	3.5	22
153	Theoretical study on 5-nitrofuryl thiosemicarbazone radicals electronic properties. Computational and Theoretical Chemistry, 2006, 770, 125-129.	1.5	5
154	Synthesis and Characterization of Thiol Containing Furoxan Derivatives as Coligands for the Preparation of Potential Bioreductive Radiopharmaceuticals. Archiv Der Pharmazie, 2006, 339, 59-66.	4.1	12
155	Development of Hypoxia Selective Cytotoxins for Cancer Treatment: An Update. Medicinal Chemistry, 2006, 2, 315-327.	1.5	15
156	Pd(thiosaccharinato)2Â·H2O, the first thiosaccharinato complex of a platinum-group metal. Journal of Coordination Chemistry, 2006, 59, 101-106.	2.2	16
157	One pot synthesis of benzyltriphenylphosphonium acetates from the corresponding activated benzylic alcohols. Arkivoc, 2006, 2006, 128-136.	0.5	11
158	Electrochemical and ESR study of 5-nitrofuryl-containing thiosemicarbazones antiprotozoal drugs. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2005, 61, 2933-2938.	3.9	26
159	Vanadium(V) complexes with salicylaldehyde semicarbazone derivatives bearing in vitro anti-tumor activity toward kidney tumor cells (TK-10): crystal structure of [VVO2(5-bromosalicylaldehyde) Tj ETQq1 1 0.784314 rgBT /Overlock 10	3.5	127
160	Chemo-selective hydrolysis of the iminic moiety in salicylaldehyde semicarbazone promoted by ruthenium. Inorganica Chimica Acta, 2005, 358, 3065-3074.	2.4	17
161	Synthesis and biological properties of new 5-nitroindazole derivatives. Bioorganic and Medicinal Chemistry, 2005, 13, 3197-3207.	3.0	63
162	Benzo[1,2-c]1,2,5-oxadiazole N-oxide derivatives as potential antitrypanosomal drugs. Part 3: Substituents-clustering methodology in the search for new active compounds. Bioorganic and Medicinal Chemistry, 2005, 13, 6324-6335.	3.0	49

#	Article	IF	Citations
163	Design, synthesis, and biological characterization of potential antiatherogenic nitric oxide releasing tocopherol analogs. Bioorganic and Medicinal Chemistry, 2005, 13, 5787-5796.	3.0	31
164	New potent 5-substituted benzofuroxans as inhibitors of Trypanosoma cruzi growth: Quantitative structureâ€“activity relationship studies. Bioorganic and Medicinal Chemistry, 2005, 13, 6336-6346.	3.0	36
165	Novel Cu(II) quinoxaline N1,N4-dioxide complexes as selective hypoxic cytotoxins. European Journal of Medicinal Chemistry, 2005, 40, 473-480.	5.5	58
166	New Synthetic Approach for the Preparation of Imidazole N3-Oxides.. ChemInform, 2005, 36, no.	0.0	0
167	Relationship Between Physicochemical Properties and Herbicidal Activity of 1,2,5-Oxadiazole N-Oxide Derivatives. Molecules, 2005, 10, 1197-1208.	3.8	11
168	Preparation of phenazine N5,N10-dioxides: Effects of benzofuroxan substituents in the outcome of their expansion reaction with phenolates. Journal of the Brazilian Chemical Society, 2005, 16, 1290-1296.	0.6	20
169	Imidazole and Benzimidazole Derivatives as Chemotherapeutic Agents. Mini-Reviews in Medicinal Chemistry, 2005, 5, 409-424.	2.4	378
170	Novel Benzo[1,2-c]1,2,5-Oxadiazole N-Oxide Derivatives as Antichagasic Agents: Chemical and Biological Studies. Letters in Drug Design and Discovery, 2005, 2, 294-301.	0.7	28
171	Pharmacological Properties of Indazole Derivatives: Recent Developments. Mini-Reviews in Medicinal Chemistry, 2005, 5, 869-878.	2.4	274
172	Phenazine 5,10-Dioxide Derivatives as Hypoxic Selective Cytotoxins. Journal of Medicinal Chemistry, 2005, 48, 21-23.	6.4	52
173	Mass spectrometry of 1,2,5-oxadiazole N-oxide derivatives: use of deuterated analogues in fragmentation pattern studies. Journal of the Brazilian Chemical Society, 2004, 15, 232-240.	0.6	11
174	Cytotoxicity of furoxans: quantitative structure-activity relationships study. Il Farmaco, 2004, 59, 405-412.	0.9	23
175	1, 2, 4-TriazineN-oxide Derivatives: Studies as Potential Hypoxic Cytotoxins. Part II.. Archiv Der Pharmazie, 2004, 337, 247-258.	4.1	15
176	1, 2, 4-TriazineN-oxide Derivatives: Studies as Potential Hypoxic Cytotoxins. Part III. Archiv Der Pharmazie, 2004, 337, 271-280.	4.1	19
177	Novel Antiprotozoal Products: Imidazole and BenzimidazoleN-Oxide Derivatives and Related Compounds. Archiv Der Pharmazie, 2004, 337, 259-270.	4.1	68
178	New Vanadium(V) Complexes with Salicylaldehyde Semicarbazone Derivatives: Synthesis, Characterization, and in vitro Insulin-Mimetic Activityâ˜† Crystal Structure of [VvO2(salicylaldehyde) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	76	
179	Cytotoxicity of Furoxans: Quantitative Structureâ€”Activity Relationships Study.. ChemInform, 2004, 35, no.	0.0	0
180	Novel Antiprotozoal Products: Imidazole and Benzimidazole N-Oxide Derivatives and Related Compounds.. ChemInform, 2004, 35, no.	0.0	0

#	Article	IF	Citations
181	1,2,4-Triazine N-Oxide Derivatives: Studies as Potential Hypoxic Cytotoxins. Part 2.. ChemInform, 2004, 35, no.	0.0	0
182	1,2,4-Triazine N-Oxide Derivatives: Studies as Potential Hypoxic Cytotoxins. Part 3.. ChemInform, 2004, 35, no.	0.0	0
183	Design, Synthesis and Biological Evaluation of New Potent 5-Nitrofuryl Derivatives as anti-Trypanosoma cruzi Agents. Studies of Trypanothione Binding Site of Trypanothione Reductase as Target for Rational Design.. ChemInform, 2004, 35, no.	0.0	0
184	In vitro activity and mechanism of action against the protozoan parasite Trypanosoma cruzi of 5-nitrofuryl containing thiosemicarbazones. Bioorganic and Medicinal Chemistry, 2004, 12, 4885-4893.	3.0	118
185	Ruthenium (II) nitrofurylsemicarbazone complexes: new DNA binding agents. European Journal of Medicinal Chemistry, 2004, 39, 377-382.	5.5	32
186	Design, synthesis and biological evaluation of new potent 5-nitrofuryl derivatives as anti-Trypanosoma cruzi agents. Studies of trypanothione binding site of trypanothione reductase as target for rational design. European Journal of Medicinal Chemistry, 2004, 39, 421-431.	5.5	56
187	Quinoxaline N , N â€²-dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi . Structureâ€“activity relationships. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 3835-3839.	2.2	79
188	Tautomerism and Reactivity in HeterocyclicN-Oxides. A Spectroscopic and Theoretical Study of BenzimidazoleN-Oxide Derivatives (N-Hydroxybenzimidazoles). Journal of Physical Chemistry A, 2004, 108, 11241-11248.	2.5	25
189	Synthesis and characterization of new ruthenium complexes with active ligands against Chagas' disease. Inorganica Chimica Acta, 2003, 344, 85-94.	2.4	53
190	Electrochemical and microsomal production of free radicals from 1,2,5-oxadiazole N-oxide as potential antiprotozoal drugs. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2003, 59, 69-74.	3.9	33
191	ESR Spin Trapping Studies of Free Radicals Generated from Nitrofuran Derivative Analogues of Nifurtimox by Electrochemical and Trypanosoma cruzi Reduction. Free Radical Research, 2003, 37, 993-1001.	3.3	46
192	ESR AND SPIN TRAPPING STUDIES OF TWO NEW POTENTIAL NTITRYPANOSOMAL DRUGS. Journal of the Chilean Chemical Society, 2003, 48, .	1.2	24
193	Characterization of [ReO(Tetramethylthiourea)4](PF6)3 in Solution: Electrochemical, NMR and Ligand Substitution Studies. Journal of Coordination Chemistry, 2002, 55, 1441-1453.	2.2	5
194	Chemotherapy of Chagas Disease: Status and New Developments. Current Topics in Medicinal Chemistry, 2002, 2, 1187-1213.	2.1	129
195	Benzo[1, 2-c]1, 2, 5-oxadiazole N-Oxide Derivatives as Potential Antitrypanosomal Drugs. Structure-Activity Relationships. Part II. Archiv Der Pharmazie, 2002, 335, 15-21.	4.1	37
196	1,2,5-Oxadiazole N-oxide derivatives as potential anti-cancer agents: synthesis and biological evaluation. Part IV. European Journal of Medicinal Chemistry, 2001, 36, 771-782.	5.5	59
197	N-Oxides as Hypoxia Selective Cytotoxins. Mini-Reviews in Medicinal Chemistry, 2001, 1, 219-231.	2.4	43
198	Synthesis and Biological Evaluation of 1,2,5-OxadiazoleN-Oxide Derivatives as Potential Hypoxic Cytotoxins and DNA-Binders. Archiv Der Pharmazie, 2000, 333, 387-393.	4.1	17

#	Article	IF	Citations
199	Synthesis and antitrypanosomal evaluation of E-isomers of 5-nitro-2-furaldehyde and 5-nitrothiophene-2-carboxaldehyde semicarbazone derivatives. Structureâ€“activity relationships.. European Journal of Medicinal Chemistry, 2000, 35, 343-350.	5.5	92
200	Synthesis and Herbicidal Activity ofN-Oxide Derivatives. Journal of Agricultural and Food Chemistry, 2000, 48, 2995-3002.	5.2	54
201	1,2,5-OxadiazoleN-Oxide Derivatives and Related Compounds as Potential Antitrypanosomal Drugs:Â Structureâ^'Activity Relationships. Journal of Medicinal Chemistry, 1999, 42, 1941-1950.	6.4	136
202	Preparation of Enamines from the Condensation of Glycine Esters with Nitro-Heterocyclic Aldehydes. Heterocycles, 1997, 45, 2023.	0.7	12
203	New hypoxiaâ€selective cytotoxines derived from quinoxaline 1,4â€dioxides. Journal of Heterocyclic Chemistry, 1995, 32, 1213-1217.	2.6	30
204	Hypoxia-Selective Agents Derived from 2-Quinoxalinecarbonitrile 1,4-Di-N-oxides. 2. Journal of Medicinal Chemistry, 1995, 38, 4488-4494.	6.4	117